The compounded GLP-1 market has matured significantly since the initial semaglutide shortage designation. Regulatory frameworks have shifted, FDA enforcement posture has evolved, and the supply chain has become considerably more complex for clinics trying to source compounded semaglutide and tirzepatide legally and reliably.

Here's what your clinic needs to understand about the GLP-1 supply chain in 2026.

Compounded GLP-1s — primarily semaglutide and tirzepatide — have been available through 503A pharmacies under FDA shortage list provisions. The regulatory basis for compounding these drugs has been tied to their presence on the FDA's drug shortage list, which has fluctuated.

As of 2026, the regulatory status of compounded GLP-1s requires active monitoring. The FDA's enforcement discretion policies, shortage list determinations, and bulk drug substance guidance have all evolved — and continue to evolve. Any pharmacy that tells you the regulatory picture is simple and settled is not giving you the full picture.

Your clinic's compliance posture depends on sourcing from pharmacies that are actively tracking these changes and adjusting their practices accordingly.

Compounded semaglutide and tirzepatide are sterile injectables that require refrigerated storage and temperature-controlled shipping. This is not optional — it's a product integrity requirement.

The cold-chain requirements for GLP-1 compounds include:

• Refrigerated storage at 2–8°C (36–46°F) from manufacture through delivery
• Validated cold-chain packaging that maintains temperature through the shipping window
• Temperature monitoring — ideally a temperature indicator included with each shipment
• Defined transit time limits — overnight shipping is the standard for most sterile compounds

A pharmacy that ships GLP-1 compounds via standard ground shipping, or without validated cold-chain packaging, is compromising product integrity. The compound may still look fine when it arrives — but potency and sterility cannot be verified without the cold-chain documentation.

Ask your pharmacy specifically: What carrier do you use? What packaging? What is your maximum transit time? Do you include temperature monitors?

Every lot of compounded GLP-1 product should come with a Certificate of Analysis from an accredited third-party laboratory. The COA should confirm:

• Potency — the compound contains the labeled amount of active ingredient
• Sterility — the product is free of microbial contamination
• Endotoxin testing — bacterial endotoxins are within acceptable limits
• Particulate matter — the solution is free of visible and sub-visible particles

If your current pharmacy is not providing COAs with every shipment, ask why. If they can't produce them, that's a compliance gap that belongs to your clinic as much as theirs.

Beyond-Use Dating (BUD) is the date after which a compounded sterile preparation should not be used. Under USP <797>, BUD dates for sterile preparations are assigned based on sterility testing and, for extended BUD dates, documented stability studies.

BUD dates matter for your clinic's inventory management. A product with a 30-day BUD date requires tighter ordering cycles than one with a 90-day BUD date backed by stability data. Ask your pharmacy:

• What is the BUD date for each product?
• What is the basis for that BUD date?
• Is extended BUD dating backed by stability studies?

Longer BUD dates are not automatically better — they need to be scientifically justified. But a pharmacy that can provide extended BUD dates with documented stability data gives your clinic more operational flexibility.

The GLP-1 supply chain has been subject to periodic back-orders and supply disruptions since 2022. Some of these have been driven by API (active pharmaceutical ingredient) availability. Others have been driven by pharmacy capacity constraints. A few have been driven by regulatory actions against specific pharmacies.

Before you commit to a 503A pharmacy as your primary GLP-1 supplier, ask about their back-order history. A pharmacy that has had multiple back-order situations in the past 12 months is a supply chain risk. Your patients can't wait for back-orders to resolve.

A reliable 503A partner should be able to tell you:

• Their current inventory position
• Their API sourcing relationships
• Their contingency plan if a specific compound is temporarily unavailable

Based on everything above, here's what a reliable 503A GLP-1 supply partner looks like in 2026:

• Active regulatory monitoring — they track FDA guidance changes and adjust proactively
• Third-party COAs on every shipment — no exceptions
• Validated cold-chain shipping — overnight, temperature-monitored, documented
• Transparent BUD dating — with stability data for extended BUD claims
• No back-order history — or a clear explanation of any past disruptions
• Patient-specific prescription requirement — operating within 503A law
• Licensed pharmacist available — for clinical questions, not just sales

If your current supplier doesn't meet these standards, it's worth evaluating your options before a compliance issue or supply disruption forces the conversation.

MedClinic Partners connects licensed providers with pre-vetted 503A supply. Our portal includes COAs with every shipment, overnight cold-chain delivery to all 50 states, and a compliance team that monitors regulatory changes so your clinic doesn't have to. NPI verification takes under 60 seconds.